Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21214925 | 0.88 | CYP2D6 (0.48) | CYP2D6KCNH2KDM4EALDH1A1GAA | |
| SCHEMBL20372781 | 0.88 | KDM4E (0.53) | CYP2D6KCNH2KDM4EALDH1A1GAA | |
| SCHEMBL18592246 | 0.86 | CYP2D6 (0.50) | CYP2D6KCNH2KDM4EALDH1A1 | |
| SCHEMBL22527260 | 0.86 | CYP2D6 (0.54) | CYP2D6KCNH2 | |
| SCHEMBL24654411 | 0.84 | CYP2D6 (0.46) | CYP2D6KCNH2KDM4EALDH1A1GAA | |
| SCHEMBL22419328 | 0.84 | CYP2D6 (0.48) | CYP2D6KCNH2KDM4EALDH1A1GAA | |
| SCHEMBL23350237 | 0.83 | CYP2D6 (0.47) | CYP2D6KCNH2KDM4EALDH1A1GAA | |
| SCHEMBL21341911 | 0.82 | MTNR1A (0.46) | — | |
| SCHEMBL20046811 | 0.82 | KDM4E (0.51) | CYP2D6KDM4EALDH1A1GAA | |
| SCHEMBL18612225 | 0.82 | SCN9A (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | CYP2D6 4632/4885KCNH2 4861/4885KDM4E 3116/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CYP2D6 3098/4885KCNH2 4792/4885KDM4E 1438/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | CYP2D6 4632/4885KCNH2 4861/4885KDM4E 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.